Chapter 01
Chapter 01
Owner-Managers
Creditors
Sell
Receive a
ownership
portion of the
interest in the
company’s
future for more
earnings in cash
than they
(dividends).
paid.
1-4
Managers
(internal
decision
Reports makers)
information
to decision
Collects and processes makers
financial information Investors
and
Creditors
(external
decision
makers)
1-5
Accounting System
Learning Objectives
2021
Let’s look at
MAXIDRIVE
CORP.’s
financial
statements.
1. Name of entity MAXIDRIVE CORP. 1-10
MAXIDRIVE CORP.
Balance Sheet
At December 31, 2021
(in thousands of dollars)
Assets
Cash $ 4,895
Accounts receivable 5,714
Inventories 8,517
Plant and equipment 7,154
Land 981
Total assets $ 27,261
Liabilities
Amounts invested and Stockholders'
in the business by Equity
Common stock stockholders. Liabilities
Accounts payable $ 7,156
Retained earnings
Notes
Past earnings not payable
distributed to stockholders. 9,000
留存收益
Total liabilities $ 16,156
Stockholders' Equity
Common stock $ 2,000
Retained earnings 9,105
Total stockholders' equity 11,105
Total liabilities and stockholders' equity $ 27,261
1-14
Economic
Resources Sources of Financing for
Economic Resources
MAXIDRIVE CORP. 1-15
Balance Sheet
At December 31, 2021
(in thousands of dollars)
Assets
Cash $ 4,895
Accounts receivable 5,714
Inventories 8,517
Plant and equipment 7,154
Land 981
Total assets $ 27,261
Liabilities and Stockholders' Equity
Liabilities
Accounts payable $ 7,156
Notes payable 9,000
Assets = Liabilities + Stockholders’ Equity
Total liabilities $ 16,156
Stockholders' Equity
Common stock $ 2,000
Retained earnings 9,105
Total stockholders' equity 11,105
Total liabilities and stockholders' equity $ 27,261
1-16
MAXIDRIVE CORP.
Income Statement
For the Year Ended December 31, 2021
(in thousands of dollars)
Revenues
1. Name
Sales of entity
revenue $ 37,436
2. Title of statement
Expenses
3. Specific
Cost of goodsperiod
sold of time (Unlike the balance
$ 26,980
sheet, this statement covers a specified
Selling, general and administrative 3,624
period of time.)
Research and development 1,982
4. Unit of measure
Interest expense 450
Total expenses 33,036
Pretax income $ 4,400
Income tax expense 1,100
Net income $ 3,300
1-17
MAXIDRIVE CORP.
The Income Statement
Income Statementreports the
For the Year
revenues Ended expenses
minus December 31, of2011
the
(in thousands of
accounting dollars)
period.
Revenues
Sales revenue $ 37,436
Expenses
Cost of goods sold $ 26,980
Selling, general and administrative 3,624
Research and development 1,982
Interest expense 450
Total expenses 33,036
Pretax income $ 4,400
Income tax expense 1,100
Net income $ 3,300
1-18
MAXIDRIVE CORP.
Income Statement
For the Year Ended December 31, 2021
(in thousands of dollars)
Revenues
Sales revenue $ 37,436
Expenses are earnings from the sale of goods
Revenues
Cost of goodsor sold $ 26,980
services to customers.
Selling, general and administrative 3,624
Revenue
Research andisdevelopment
recognized in the period in which
1,982
goods
Interest and services are sold, not necessarily
expense 450
Totalthe period in which cash is received. 33,036
expenses
Pretax income $ 4,400
Income tax expense 1,100
Net income $ 3,300
1-19
Revenues
Revenues
MAXIDRIVE CORP.
Income Statement
For the Year Ended December 31, 2021
(in thousands of dollars)
Cost of
Revenues The cost to produce products sold this
goods
Sales sold period.
revenue $ 37,436
Expenses
Selling,
Operating expenses not directly related
Cost of goods
general and sold $ 26,980
to production.
administrative
Selling, general and administrative 3,624
Research
Researchand anddevelopment 1,982 new
Expenses incurred to develop
Interest
developmentexpenseproducts. 450
Total expenses 33,036
Interest
Pretax income The cost of using borrowed funds.
$ 4,400
expense
Incometax
Income tax expense 1,100
Income taxes on current period’s pretax
Netexpense
income income. $ 3,300
1-23
Expenses
Expenses
Revenues
Sales revenue $ 37,436
Expenses
Cost of goods sold $ 26,980
Selling, general and administrative 3,624
Research and development 1,982
Interest expense 450
Total expenses 33,036
Pretax income $ 4,400
Income tax expense 1,100
Net income $ 3,300
1-26
MAXIDRIVE CORP.
Statement of Stockholders' Equity
For the Year Ended December 31,2021
(in thousands of dollars)
Common Retained
stock earnings
Balance December 31,2020 $ 2,000.00 $ 6,805.00
1. Name
Net incomeofforentity
2021 3,300.00
2. Title offorstatement
Dividend 2021 -1,000.00
3. Specific period of time (Like the income
Balance December 31,2021 $ 2,000.00 $ 9,105.00
statement, this statement covers a specified
period of time.)
4. Unit of measure
1-27
MAXIDRIVE CORP.
Statement of Stockholders' Equity
For the Year Ended December 31,2021
(in thousands of dollars)
Common Retained
stock earnings
Balance December 31,2020 $ 2,000.00 $ 6,805.00
Net income for 2021 3,300.00
Dividend for 2021 -1,000.00
Balance December 31,2021 $ 2,000.00 $ 9,105.00
1-30
net income is
usually not equal
to the change
in cash for
the period.
1-31
MAXIDRIVE CORP.
Statement of Cash Flows
For the Year Ended December 31, 2021
(in thousands of dollars)
Revenues
Sales revenue $ 37,436
Expenses
Cost of goods sold $ 26,980
Selling, general and administrative 3,624
Research and development 1,982
Interest expense 450
Total expenses 33,036
Pretax income $ 4,400
Income tax expense 1,100
Net income $ 3,300
1-38
Notes
Price/Earnings Ratio
Learning Objectives
SEC:
CSRC (China Securities Regulatory Commission,
中国证券监督管理委员会,证监会)
FASB:
Accounting Department of the Ministry of Finance
(财政部会计司)
1-49
International Perspective
The International Accounting Standards Board and
Global Convergence of Accounting Standards
Since 2002, there has been substantial movement toward the adoption of
International Financial Reporting Standards (IFRS) issued by the
International Accounting Standards Board (IASB).
In the United States, the Securities and Exchange Commission now allows
foreign companies whose stock is traded in the U.S. to use IFRS and is
considering requiring the use of IFRS for U.S. domestic companies by 2015.
1-50
Learning Objectives
Kangmei Pharmaceutical
Kangmei Pharmaceutical, founded in 1997, is a large
pharmaceutical enterprise specializing in traditional Chinese medicine
decoction pieces, chemical active pharmaceutical ingredients, and
pharmaceutical manufacturing. It integrates drug production, R&D, as
well as the marketing of pharmaceuticals and medical devices. The
company was listed on the Shanghai Stock Exchange in 2001
(600518).
In January 2014, Kangmei obtained a direct selling license issued
by the Ministry of Commerce, and its revenue and net profit grew
steadily. In 2015, as China became the world’s second-largest
pharmaceutical market, Kangmei, benefiting from the domestic
pharmaceutical industry boom, became the first listed pharmaceutical
company in China’s capital market to surpass RMB 100 billion in
market capitalization.
1-55
Kangmei Pharmaceutical
The responsible parties were held
False Records liable for RMB 2.459 billion in damages
and received a 12-year prison sentence.
End of Chapter 1
1-57
1. Reading: Chapter 1
2. Overview four financial statements
3. Get familiar with the main categories in each
financial statement.
4. Role & history of GAAP
5. The importance of ethics